Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PHIP

Gene summary for PHIP

Gene summary.

Gene information	Species	Human
	Gene symbol	PHIP
	Gene ID	55023
	Gene name	pleckstrin homology domain interacting protein
	Gene Alias	BRWD2
	Cytomap	6q14.1
	Gene Type	protein-coding
	GO ID	GO:0000278
	UniProtAcc	Q8WWQ0

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
55023	PHIP	CA_HPV_1	Human	Cervix	CC	1.96e-05	-8.89e-02	0.0264
55023	PHIP	CCI_1	Human	Cervix	CC	5.91e-03	6.57e-01	0.528
55023	PHIP	CCI_2	Human	Cervix	CC	4.54e-09	6.65e-01	0.5249
55023	PHIP	CCI_3	Human	Cervix	CC	8.57e-07	9.79e-01	0.516
55023	PHIP	L1	Human	Cervix	CC	1.75e-04	-1.30e-01	0.0802
55023	PHIP	HTA11_3410_2000001011	Human	Colorectum	AD	6.25e-18	-7.22e-01	0.0155
55023	PHIP	HTA11_2487_2000001011	Human	Colorectum	SER	1.73e-08	-7.27e-01	-0.1808
55023	PHIP	HTA11_2951_2000001011	Human	Colorectum	AD	4.29e-03	-8.68e-01	0.0216
55023	PHIP	HTA11_3361_2000001011	Human	Colorectum	AD	5.05e-04	-6.48e-01	-0.1207
55023	PHIP	HTA11_696_2000001011	Human	Colorectum	AD	5.92e-22	-6.24e-01	-0.1464
55023	PHIP	HTA11_866_2000001011	Human	Colorectum	AD	5.20e-07	-4.56e-01	-0.1001
55023	PHIP	HTA11_7862_2000001011	Human	Colorectum	AD	9.88e-06	-8.07e-01	-0.0179
55023	PHIP	HTA11_866_3004761011	Human	Colorectum	AD	3.95e-12	-6.75e-01	0.096
55023	PHIP	HTA11_9408_2000001011	Human	Colorectum	AD	8.33e-03	-9.26e-01	0.0451
55023	PHIP	HTA11_8622_2000001021	Human	Colorectum	SER	4.42e-02	-6.41e-01	0.0528
55023	PHIP	HTA11_10711_2000001011	Human	Colorectum	AD	4.24e-06	-6.65e-01	0.0338
55023	PHIP	HTA11_7696_3000711011	Human	Colorectum	AD	9.14e-18	-5.79e-01	0.0674
55023	PHIP	HTA11_6818_2000001021	Human	Colorectum	AD	4.82e-06	-5.49e-01	0.0588
55023	PHIP	HTA11_99999970781_79442	Human	Colorectum	MSS	2.26e-13	-5.31e-01	0.294
55023	PHIP	HTA11_99999971662_82457	Human	Colorectum	MSS	2.25e-05	-3.75e-01	0.3859

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004578710	Esophagus	ESCC	positive regulation of cell cycle	196/8552	313/18723	9.27e-10	2.24e-08	196
GO:00070883	Esophagus	ESCC	regulation of mitotic nuclear division	78/8552	110/18723	6.96e-08	1.21e-06	78
GO:2001237111	Esophagus	ESCC	negative regulation of extrinsic apoptotic signaling pathway	69/8552	97/18723	3.23e-07	4.55e-06	69
GO:190165319	Esophagus	ESCC	cellular response to peptide	208/8552	359/18723	1.68e-06	2.01e-05	208
GO:00517831	Esophagus	ESCC	regulation of nuclear division	90/8552	139/18723	4.30e-06	4.60e-05	90
GO:00900689	Esophagus	ESCC	positive regulation of cell cycle process	142/8552	236/18723	4.79e-06	5.08e-05	142
GO:0043434111	Esophagus	ESCC	response to peptide hormone	234/8552	414/18723	4.93e-06	5.21e-05	234
GO:002260420	Esophagus	ESCC	regulation of cell morphogenesis	180/8552	309/18723	5.19e-06	5.45e-05	180
GO:003286918	Esophagus	ESCC	cellular response to insulin stimulus	124/8552	203/18723	6.63e-06	6.75e-05	124
GO:003286818	Esophagus	ESCC	response to insulin	156/8552	264/18723	7.21e-06	7.20e-05	156
GO:007137516	Esophagus	ESCC	cellular response to peptide hormone stimulus	166/8552	290/18723	4.48e-05	3.55e-04	166
GO:000836018	Esophagus	ESCC	regulation of cell shape	92/8552	154/18723	3.00e-04	1.81e-03	92
GO:00082869	Esophagus	ESCC	insulin receptor signaling pathway	66/8552	116/18723	9.76e-03	3.37e-02	66
GO:200123312	Liver	Cirrhotic	regulation of apoptotic signaling pathway	163/4634	356/18723	2.62e-18	4.43e-16	163
GO:20012347	Liver	Cirrhotic	negative regulation of apoptotic signaling pathway	102/4634	224/18723	8.40e-12	5.60e-10	102
GO:002260412	Liver	Cirrhotic	regulation of cell morphogenesis	127/4634	309/18723	1.45e-10	7.44e-09	127
GO:009719112	Liver	Cirrhotic	extrinsic apoptotic signaling pathway	97/4634	219/18723	1.82e-10	9.11e-09	97
GO:200123612	Liver	Cirrhotic	regulation of extrinsic apoptotic signaling pathway	72/4634	151/18723	7.80e-10	3.62e-08	72
GO:000836012	Liver	Cirrhotic	regulation of cell shape	69/4634	154/18723	4.21e-08	1.36e-06	69
GO:004343412	Liver	Cirrhotic	response to peptide hormone	149/4634	414/18723	1.70e-07	4.49e-06	149

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PHIP

SNV

Missense_Mutation

novel

c.4808N>T

p.Ser1603Leu

p.S1603L

Q8WWQ0

protein_coding

tolerated_low_confidence(0.27)

benign(0.154)

TCGA-AO-A03P-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

letrozole

PHIP

SNV

Missense_Mutation

rs200729688

c.4529N>A

p.Arg1510Gln

p.R1510Q

Q8WWQ0

protein_coding

tolerated_low_confidence(0.08)

benign(0.388)

TCGA-AO-A0J5-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Other, specify in notesBisphosphonate

zoledronic

PHIP

SNV

Missense_Mutation

rs754515374

c.4120N>G

p.Asn1374Asp

p.N1374D

Q8WWQ0

protein_coding

deleterious(0.03)

benign(0.003)

TCGA-B6-A1KF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PHIP

SNV

Missense_Mutation

c.3457N>A

p.Asp1153Asn

p.D1153N

Q8WWQ0

protein_coding

deleterious(0.04)

benign(0.321)

TCGA-BH-A0HP-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

PHIP

SNV

Missense_Mutation

c.2326N>A

p.Ala776Thr

p.A776T

Q8WWQ0

protein_coding

tolerated(0.63)

benign(0)

TCGA-BH-A18G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PHIP

SNV

Missense_Mutation

c.3929G>A

p.Arg1310His

p.R1310H

Q8WWQ0

protein_coding

deleterious(0.01)

probably_damaging(0.987)

TCGA-BH-A5IZ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

PHIP

SNV

Missense_Mutation

c.3754N>A

p.Val1252Met

p.V1252M

Q8WWQ0

protein_coding

deleterious(0)

probably_damaging(0.994)

TCGA-BH-A6R8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PHIP

SNV

Missense_Mutation

c.2887N>A

p.Glu963Lys

p.E963K

Q8WWQ0

protein_coding

deleterious(0)

benign(0.07)

TCGA-C8-A12T-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PHIP

SNV

Missense_Mutation

c.1292N>A

p.Ala431Asp

p.A431D

Q8WWQ0

protein_coding

deleterious(0)

possibly_damaging(0.908)

TCGA-E9-A1RF-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

tamoxiphen

PHIP

SNV

Missense_Mutation

c.4031N>G

p.Pro1344Arg

p.P1344R

Q8WWQ0

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-GM-A2DH-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxol

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1